A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year.

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, "does not currently demonstrate value" for money.

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE. GB is the first country in Europe to approve amyloid inhibitor Kisunla (donanemab) and only the third to do so worldwide after the US and Japan.

This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.

A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns. Donanemab was on Wednesday approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for people in Britain ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.

Donanemab has been hailed as 'game changer' but it's likely the price tag will bar it from being available to nearly one million Brits.